| Virtual Simulation Versus High-Fidelity Mannequin Simulation (NCT05041049) | McGill University Health Centre/Research Institute of the McGill University Health Centre | |
| ZX008 Expanded Access Protocol (NCT03780127) | Zogenix, Inc. | |
| AveXis Managed Access Program Cohort for Access to AVXS-101 (NCT03955679) | United BioSource, LLC | |
| JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase (NCT04943952) | Jazz Pharmaceuticals | |
| Use of NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries (NCT04040660) | MediWound Ltd | |
| Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients (NCT06279728) | Daiichi Sankyo | |
| Expanded Access Program of Ponatinib (NCT01592136) | Ariad Pharmaceuticals | |
| Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients (NCT04552691) | Chiesi Farmaceutici S.p.A. | |
| Expanded Access Program for Tofersen in Participants With Superoxide Dismutase 1-Amyotropic Lateral Sclerosis (NCT04972487) | Biogen | |
| An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1 (NCT03259633) | AstraZeneca | |
| Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer (NCT04377152) | University of California, San Francisco | |
| Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid (NCT05906706) | Regeneron Pharmaceuticals | |
| Emergency/Compassionate Use - Muscular VSD Occluder (NCT00590382) | Abbott Medical Devices | |
| EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx (NCT02705313) | Advanced Accelerator Applications | |
| Compassionate Use of Dupilumab (NCT04776694) | Regeneron Pharmaceuticals | |
| Dupilumab Compassionate Use Study (NCT03020810) | Sally E. Wenzel MD | |
| Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC) (NCT01931306) | Boehringer Ingelheim | |
| Assess Safety and Probable Benefit of the EXCOR® Pediatric Ventricular Assist Device Under a Continued Access Protocol (NCT01242891) | Berlin Heart, Inc | |
| Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer (NCT04452136) | Jeanne Link | |
| Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis (NCT00989807) | Gilead Sciences | |
| Single Patient Treatment of Posaconazole in Invasive Fungal Infections (Study P05113) (NCT00686621) | Merck Sharp & Dohme LLC | |
| An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic (NCT04395508) | Genentech, Inc. | |
| Compassionate Use of IV Fish Oil for Parenteral Nutrition (PN) Liver Injury (NCT01425567) | The University of Texas Health Science Center at San Antonio | |
| Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism (NCT05654701) | Ascendis Pharma Bone Diseases A/S | |
| 18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer (NCT04809584) | Stanford University | |
| Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma (NCT02477891) | Janssen Research & Development, LLC | |
| Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome (NCT01983722) | Children's Hospital Medical Center, Cincinnati | |
| Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis (NCT00650026) | Abbott | |
| Compassionate Use of Omegaven (NCT02778698) | Geisinger Clinic | |
| Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC) (NCT03089658) | Merck KGaA, Darmstadt, Germany | |
| An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma (NCT04136808) | Astellas Pharma Global Development, Inc. | |
| An Expanded Access Program for Risdiplam in Participants With Spinal Muscular Atrophy (SMA) (NCT04256265) | Genentech, Inc. | |
| Compassionate Use of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (NCT06003881) | Regeneron Pharmaceuticals | |
| Treatment of Dravet Syndrome With Fenfluramine (Expanded Access Protocol) (NCT04437004) | University of California, Los Angeles | |
| Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes (NCT01724580) | Eli Lilly and Company | |
| A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma (NCT01076517) | Stanford University | |
| Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy (NCT01606982) | Astellas Pharma Global Development, Inc. | |
| Expanded Access to Nivolumab (Opdivo) (NCT03126643) | Bristol-Myers Squibb | |
| Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma (NCT00730444) | GE Healthcare | |
| Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease (NCT04914247) | Actelion | |
| ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma. (NCT00040625) | Eli Lilly and Company | |
| VX-445/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients Heterozygous for F508del Mutation and a Minimal Function Mutation (F/MF Genotypes) (NCT04058210) | Vertex Pharmaceuticals Incorporated | |
| Margetuximab Expanded Access Program (NCT03133988) | TerSera Therapeutics LLC | |
| Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease (NCT04040894) | Amgen | |
| Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer (NCT04220203) | Seagen, a wholly owned subsidiary of Pfizer | |
| An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant (NCT03147742) | Incyte Corporation | |
| Pre-Approval Access for Administration of Daratumumab Subcutaneously (SC) in Participants Who Are Unable to Receive Intravenous (IV) Daratumumab (NCT04264884) | Janssen Research & Development, LLC | |
| Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease (NCT01410500) | Amgen | |
| Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma (NCT05757973) | Janssen Research & Development, LLC | |
| Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria (NCT04056481) | Alnylam Pharmaceuticals | |
| Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C (NCT01779518) | Gilead Sciences | |
| Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma (NCT01377532) | University of California, San Francisco | |
| Islet Transplantation in Type I Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol (NCT03791567) | CellTrans Inc. | |
| EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML (NCT02533115) | Jazz Pharmaceuticals | |
| Expanded Access for IMMU-132 (NCT04320693) | Gilead Sciences | |
| Expanded Access for CC-486 (NCT03723135) | Celgene | |
| Zenith® Fenestrated Abdominal Aortic Aneurysm (AAA) Endovascular Graft Continued Access Study (NCT02577562) | Cook Group Incorporated | |
| Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study (NCT02355054) | Washington University School of Medicine | |
| Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation (NCT05162443) | Bristol-Myers Squibb | |
| Lorlatinib - PF-06463922 (NCT03127618) | Pfizer | |
| Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular Dystrophy (NCT02592941) | PTC Therapeutics | |
| Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use (NCT06877676) | Janssen Research & Development, LLC | |
| TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens. (NCT00245739) | Tibotec Pharmaceuticals, Ireland | |
| Mentor Adjunct Study for Silicone Gel-Filled Mammary Prosthesis (NCT00948948) | Mentor Worldwide, LLC | |
| Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion (NCT03025360) | Bayer | |
| ELX/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients With at Least One F508del Mutation (NCT04702360) | Vertex Pharmaceuticals Incorporated | |
| Copper Histidinate Treatment for Menkes Disease (NCT04074512) | Sentynl Therapeutics, Inc. | |
| Expanded Access Program for Epcoritamab (NCT05733650) | Genmab | |
| Safer Parenteral Nutrition in Pediatric Short Bowel Syndrome to Decrease Liver Damage (NCT01861834) | Georgetown University | |
| Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM) (NCT05164250) | Regeneron Pharmaceuticals | |
| Himalaya Early Access Program (NCT05345678) | AstraZeneca | |
| Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial (NCT00071708) | Eli Lilly and Company | |
| Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC (NCT04204928) | Blueprint Medicines Corporation | |
| Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma (NCT01632826) | Celgene | |
| Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP) (NCT05770219) | Takeda | |
| Expanded Access Study for Renal Transplant Patients With Envarsus XR ™ (NCT02411604) | Veloxis Pharmaceuticals | |
| Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation (NCT03817515) | Aadi Bioscience, Inc. | |
| LUX Lung Special Access Scheme Australia Named Patient Use (NPU) (NCT01209650) | Boehringer Ingelheim | |
| Expanded Access of Pimavanserin for Patients With PD Psychosis (NCT02762591) | ACADIA Pharmaceuticals Inc. | |
| Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity (NCT00481559) | BTG International Inc. | |
| Early Access Program of Lazertinib in Republic of Korea (NCT04829422) | Yuhan Corporation | |
| Zenith® TX2® Low Profile TAA Endovascular Graft (NCT02471781) | Cook Group Incorporated | |
| The Expanded Access Use of Viltolarsen in Duchenne Muscular Dystrophy With Confirmed Exon 53 Amenable Mutation (NCT04337112) | NS Pharma, Inc. | |
| Vorasidenib Expanded Access Program (NCT05592743) | Servier | |
| The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol (NCT00438789) | Alexion Pharmaceuticals, Inc. | |
| Phase II Clinical Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft (NCT01327742) | Bolton Medical | |
| Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation (NCT03906331) | Eli Lilly and Company | |
| International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer (NCT02065765) | Eli Lilly and Company | |
| Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP) (NCT02496689) | Alexion Pharmaceuticals, Inc. | |
| Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia (NCT01869803) | Wake Forest University Health Sciences | |
| SMOF Lipid for Children With Parenteral Nutrition Induced Liver Injury (NCT02412566) | Baylor College of Medicine | |
| Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis (NCT03278314) | Vertex Pharmaceuticals Incorporated | |
| Prometra's Utilization in Mitigating Pain II (NCT00866164) | Flowonix Medical | |
| Compassionate Use of Evinacumab (NCT06500598) | Regeneron Pharmaceuticals | |
| An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer (NCT02211222) | Eisai Inc. | |
| 18F-FDG PET Imaging in Cardiac Sarcoidosis (NCT01764191) | British Columbia Cancer Agency | |
| An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS) (NCT05183802) | Rhythm Pharmaceuticals, Inc. | |
| Sapropterin Expanded Access Program (NCT00484991) | BioMarin Pharmaceutical | |
| Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome (NCT02189720) | Catalyst Pharmaceuticals, Inc. | |
| Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants (NCT02534077) | Pediatrix | |